ATLANTA, GA – – (Newsfile Corp. – February 1, 2023) – – Holzer & Holzer, LLC informs investors that a class action lawsuit has been filed against Invivyd, Inc. (“Invivyd” or the “Company”) f/k/a Adagio Therapeutics, Inc. (NASDAQ: IVVD). The lawsuit alleges Invivyd made materially false and/or misleading statements and/or failed to disclose material adverse facts, including: (a) that the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim its product, ADG20, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (b) that defendants’ claims regarding ADG20’s efficacy against Omicron lacked a reasonable factual basis; and (c) that ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.
If you bought shares of Invivyd between November 29, 2021 and December 14, 2021 and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at firstname.lastname@example.org or Joshua Karr, Esq. at email@example.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at https://holzerlaw.com/case/invivyd/ to learn more.
The deadline to ask the court to be appointed lead plaintiff in the case is April 3, 2023.
Lead Plaintiff Deadline Has Passed
April 3, 2023